Cited 14 times in
Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천근아 | - |
dc.date.accessioned | 2015-12-28T11:09:17Z | - |
dc.date.available | 2015-12-28T11:09:17Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1738-1088 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138812 | - |
dc.description.abstract | In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 19~30 | - |
dc.relation.isPartOf | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Psychiatry (정신과학) | - |
dc.contributor.googleauthor | Yeon Jung Lee | - |
dc.contributor.googleauthor | Soo Hyun Oh | - |
dc.contributor.googleauthor | Chanmin Park | - |
dc.contributor.googleauthor | Minha Hong | - |
dc.contributor.googleauthor | Ah Rah Lee | - |
dc.contributor.googleauthor | Hee Jeong Yoo | - |
dc.contributor.googleauthor | Chan Young Shin | - |
dc.contributor.googleauthor | Keun Ah Cheon | - |
dc.contributor.googleauthor | Geon Ho Bahn | - |
dc.identifier.doi | 10.9758/cpn.2014.12.1.19 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04027 | - |
dc.relation.journalcode | J00609 | - |
dc.identifier.eissn | 2093-4327 | - |
dc.identifier.pmid | 24851117 | - |
dc.subject.keyword | Child development disorders, pervasive | - |
dc.subject.keyword | Drug therapy | - |
dc.subject.keyword | Etiology | - |
dc.contributor.alternativeName | Cheon, Keun Ah | - |
dc.contributor.affiliatedAuthor | Cheon, Keun Ah | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 19 | - |
dc.citation.endPage | 30 | - |
dc.identifier.bibliographicCitation | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, Vol.12(1) : 19-30, 2014 | - |
dc.identifier.rimsid | 54937 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.